Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Tmunity is formed for cellular therapies

by Lisa M. Jarvis
January 29, 2018 | A version of this story appeared in Volume 96, Issue 5

Tmunity Therapeutics, a biotech firm cofounded by cellular therapy pioneer Carl June, has raised $100 million in its first formal round of financing. Ping An Ventures, Gilead Sciences, and the Parker Institute for Cancer Immunotherapy are among the investors in Tmunity, which was launched in 2016 by June and other University of Pennsylvania researchers. Led by Usman Azam, former head of Novartis’s cell and gene therapies unit, the firm is working on T-cell immunotherapies for cancer. The funding is one of several recent large series A rounds. Earlier this month, Gossamer Bio and BioNTech raised $100 million and $270 million, respectively.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.